Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascul...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Via Medica
2022-07-01
|
| Цуврал: | Cardiology Journal |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://journals.viamedica.pl/cardiology_journal/article/view/75703 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|